Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA STARPORT
NCT04787744Phase 3Active, not recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jul 2021
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Castration-resistant prostate cancer-free survival at 4 years. Started Jul 2021; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04787744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787744.